Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Roche Intent on Discovering Innovative Medicines in China
- ChinaBio Today submits: Roche (RHHBY.PK) has broken ground on an expansion of its facilities at its site in Shanghai’s Zhangjiang Hi-Tech Park, an ambitious expansion that seeks to provide the backbone for the next ten years of the company’s China growth. In addition, Roche has established an office for...
- External links 2008-11-04
- Wuxi, Pfizer Strengthen Relationship in New Deal
- ChinaBio Today submits: WuXi PharmaTech WX has signed a new three-year CRO deal with Pfizer PFE to collaborate on in-vitro ADME (Absorption, Distribution, Metabolism and Excretion) services. Although WuXi has already been providing the services to Pfizer, WuXi said the new agreement “strengthens an already productive relationship.” WuXi also...
- External links 2008-11-08
- Charles River Blames Slowdown on Biopharmas' Need to Conserve Cash
- ChinaBio Today submits: Charles River Labs CRL reduced its 2008 profit guidance by 3% because its CRO clients are delaying scheduled tests until next year. The trend caused a small slowing of the company’s growth rate in Q3, but the effect in Q4 will be more pronounced, according to...
- External links 2008-11-08
- China Medical Develops Predictor for Biologic Cancer Drug Success
- ChinaBio Today submits: China Medical Technologies CMED has developed two proprietary molecular diagnostic kits that detect abnormalities in epidermal growth factor receptor (EGFR) among patients with non-small cell lung cancer (NSCLC). EGFR abnormalities are important biomarkers for the biologic cancer drugs Iressa from AstraZeneca AZN and Tarceva from Genentech...
- External links 2008-11-21
- Lilly Adds Oncology Target to Chi-Med Collaboration
- ChinaBio Today submits: Eli Lilly LLY has expanded its drug discovery and development partnership with Hutchison China Meditech Ltd (LSE: HCM) , adding another oncology target to the agenda. When the two companies set up their partnership last year, the initial areas of concentration were specified targets in oncology...
- External links 2008-11-25
- WuXi Shuts Down Manufacturing Operation as Economy Hits Small Pharmas
- ChinaBio Today submits: WuXi PharmaTech WX announced it will discontinue its U.S.-based biologics manufacturing business, which is currently operating out of its Philadelphia facility. The operation was part of WuXi’s controversial AppTec acquisition, completed earlier this year. In a conference call, WuXi management said the dynamics of...
- External links 2008-12-02
- Abbott Launches First Research Center in Southeast Asia
- ChinaBio Today submits: Abbott Labs (NYSE: ABT) opened an R&D facility in Singapore's Biopolis research park, the company’s first research lab in Southeast Asia. The new lab will conduct stability studies, including studies on active pharmaceutical ingredients and novel formulations, which will support regulatory requirements for new products around...
- External links 2009-01-21
- BMP Sunstone Announces 36% Increase in 2009 Guidance
- ChinaBio Today submits: BMP Sunstone Company (NSDQ: BJGP) announced its financial guidance for 2009, calling for a 36% increase in revenue to between $150 million and $160 million. Non-GAAP net income is predicted to rise 70% to a range of $10 million to $13 million. For 2008, BMP Sunstone...
- External links 2009-01-22
- Roche Gets Creative with Deal Making in China
- ChinaBio Today submits: Roche Holding AG (RHHBY.PK), the pharmaceutical giant based in Switzerland, is considering a new model of entrepreneurial partnership for China. Roche may help its employees set up their own companies, spinning off compounds in development to them, while maintaining some sort of post-partum relationship between the...
- External links 2009-02-10
- Is Pharmacyclics Eying China?
- ChinaBio Today submits: Pharmacyclics, Inc. (NSDQ: PCYC), a Sunnyvale, CA biopharma with four drugs in clinical development, may be developing a business model that involves China. However, at this stage, the evidence for such a move is sketchy, at best. The following is what we know, and you can...
- External links 2009-02-22
- Agilent Publishes Stem Cell Discovery in China Collaboration
- ChinaBio Today submits: In a collaboration, Agilent Technologies Inc. (NYSE: A), together with a team from the Shanghai Institutes for Biological Sciences and Tongi University, discovered new insight into how adult cells can be coaxed into a pluripotent state where they act like embryonic stem cells (ESC). Pluripotent stem...
- External links 2009-04-01
- NeoStem Raises $11 Million to Increase China Operations
- ChinaBio Today submits: NeoStem, Inc. (AMEX: NBS) raised $11 million from a private placement with Asian investors. Much of the money will be spent to increase the company’s China operations. In November 2008, NeoStem gained control over a China regenerative medical therapy company, Shandong New Medicine Research Institute of...
- External links 2009-04-14
- Lilly Emphasizes China in Strategic Plans
- ChinaBio Today submits: Eli Lilly and Company (NYSE: LLY) will not attempt a large-scale merger similar to the ones currently in the big pharma news; instead, the company says it will continue to implement its diversified drug development model, with a healthy dose of partnerships adding to in-house R&D....
- External links 2009-04-16
- China Biologic's Impressive Order from India
- ChinaBio Today submits: China Biologic Products (CBPO.OB) reported a $5.3 million order for its plasma products for distribution in India. China Biologic began its initiative to sell products internationally only in the last year. The order is for Human Immunoglobulin (ph4) for IV Injection [IVIG] 5g/100ml product, which will...
- External links 2009-04-28
- Sinovac Rises on Swine Flu Ramifications
- ChinaBio Today submits: Sinovac Biotech SVA received an order for 87 million RMB ($12.8 million) of its inactivated hepatitis A vaccine, Healive, from China's Ministry of Public Health. In 2008, Sinovac recorded revenues of $46.5 million, 88% of which came from Healive. Sinovac said that the MOH order is...
- External links 2009-04-29
- NeoStem Makes Headway in Stem Cell Industry
- ChinaBio Today submits: NeoStem, Inc. NBS in-licensed worldwide rights to Primcel, a mesenchymal bone marrow stem cell product that, in early clinical studies, shows promise of accelerating the healing of chronic wounds. NeoStem has opened adult stem cell collection sites in the US and has invested in regenerative medicine...
- External links 2009-05-06
- Roche Launches China Biopharma Application Support Center
- ChinaBio Today submits: Roche Applied Science, the research tools division of Swiss biopharma Hoffman-La Roche (RHHBY.PK), has launched an Application Support Center in Shanghai. The center will offer hotline support to Asia Pacific biopharma researchers who are using Roche tools. There is no charge for the service. The service...
- External links 2009-05-31
- China Sky One Receives Seventh New Product Approval for 2009
- ChinaBio Today submits: China Sky One Medical CSKI was given approval by the SFDA to produce Diclofenac Sodium eye drops. The new product will be used to treat eye conditions including uveitis, keratitis and sclerotitis. Diclofenac Sodium eye drops are able to inhibit formation of unwanted blood vessels in...
- External links 2009-06-03
- Commonwealth Biotechnologies Expands Presence in Peptides
- ChinaBio Today submits: Commonwealth Biotechnologies, Inc. (NSDQ: CBTE) has agreed to acquire privately owned GL Biochem Shanghai Ltd., a manufacturer of peptide products and reagents. In 2008, GL Biochem produced $13 million of revenue and $2 million of net income, representing a compound annual growth rate of 40%. In...
- External links 2009-06-11
- China Biopharma Companies Seize Opportunities in U.S. Real Estate
- ChinaBio Today submits: As China biopharma continues to evolve, the once dominant model of Western companies seeking opportunities in Asia, a uni-directional relationship, shows signs of giving way to increased bi-directional cooperation between West and East. In the last eighteen months, we have seen two large transactions in which...
- External links 2009-06-12
- << Previous
- page 1 of 3
- Next >>
Presented by American Express